PHP26 IMPOVERISHING MEDICINES: A CROSS-COUNTRY COMPARISON OF THE AFFORDABILITY OF MEDICINES
Niëns LM Erasmus University Rotterdam, Rotterdam, The Netherlands OBJECTIVES: In low-and middle-income countries medicine costs account for a substantial part of total health care costs (WHO estimate: 25-70%). In these countries many patients pay for medicines out-of-pocket. This study's aim was to calculate the affordability of four essential medicines (salbutamol inhaler (100 mcg/dose), glibenclamide (5 mg), atenolol (50 mg) and amoxicillin (250 mg)) for 17 low-and middleincome countries. METHODS: Previous research expressed affordability of medicines in the number of days' wages of the lowest paid unskilled government worker. Using medicine prices from a joint project between Health Action International & WHO, and expenditure data and income distributions from the World Bank, this study applied a more common measure of affordability of medicines based on impoverishment (i.e., percentage below US$1 or $2 per day after medicine procurement). Affordability is calculated for Originator Brand (OB) and Lowest Priced Generic (LPG) medicines in both the public and private sector. RESULTS: OB medicines are less affordable than LPG medicines. Impoverishment rates (IRs) between OB and LPG medicines vary substantially; 10.8% vs. 4.0% (OB vs. LPG below US$1, public sector atenolol, Philippines). IRs of up to 33.6% were found (below US$1, OB private sector amoxicillin, Indonesia). IRs in low-income countries are lower than in middle-income countries due to high numbers already living below US$1 or $2 per day. We distinguish between those being impoverished and those for whom medicines are unaffordable in the first place (i.e. below US$1 or $2 before medicine procurement). In the public sector IRs are lower than in the private sector but availability of medicines is low. CONCLUSIONS: In low-and middle-income countries medicine prices in relation to available income are such that obtaining necessary medication will impoverish large numbers of people. These results call for action by politicians, policymakers, and civil societies.
PHP27 ASSESSMENT OF THE INTERNATIONAL NONPROPRIETARY NAMES (INN) PRESCRIBING PILOT PROJECT IN SOUTH KOREA
Kim JY, Lee EK Sook Myung Women's University, Seoul, South Korea OBJECTIVES: The pilot project of International Nonproprietary Names (INN) was implemented over nine months at the National Medical Center (NMC). This study aimed to assess the impact of INN on its prescribing rate and drug cost savings. METHODS: National health insurance claims data were used to analyze the extent to which INN prescribing was conducted for outpatients at NMC, and to know which drugs were dispensed at pharmacies. INN prescribing rates were compared by month, type of clinics, patient's characteristics and drug classifications. Also, drug cost savings were compared with brand name in terms of average cost, the rate of the highest-priced drug, and total drug expenditure. RESULTS: INN prescribing rate was 31.76%. The rate was higher for non-prescription drugs (30.2%) than for prescription drugs (15.92%). The rate increased with the age of patient; it was higher for patients with health insurance (33.61%) than those on Medicaid (26.75%); the rate was higher for re-visit (33.7%) than the first visit (9.94%). Specialties with the highest rate were Internal Medicine and Neurology. Average cost of INN prescribing was lower than the brand name prescribing before and during pilot project. Total drug expenditure was reduced by 3.63% compared to before the pilot project, and by 4.58% compared to brand name prescription during pilot project. CONCLUSIONS: In conclusion, doctors' INN prescribing rate was 31.76% and drug cost savings compared to brand name prescription was 3.63% and 4.58% respectively, for before and during pilot project. To achieve better results, active participation of doctors in INN prescribing and dispensing low-priced drug by pharmacists are essential. ement of the system of pharmaceutical care. Polish Pharmaceutical Council accepted a programme called the Strategy of the Pharmaceutical Care in Poland over two years ago. Introducing the pharmaceutical care is not obligatory, but more and more frequently it is perceived as an element of the long-term strategy of pharmacies development. The survey was conducted in 2009. Apart from identification of social expectations concerning pharmaceutical care, the survey aimed at determining to what extent is the society informed about this process. The survey was conducted in a group of 848 responders. In 65% of the cases, the patients did not encounter the pharmaceutical care programme and were not informed that it is being implemented by the Polish Health Service, 73% of responders were interested in taking part in the care process, expecting some benefits. The responders expect the following benefits: 29%-financial savings, 28%-avoiding drug interfinancial savings, 28%-avoiding drug inter--avoiding drug interavoiding drug interactions, 24%-reduction of quantity of taken preparations, 14%-control to take -reduction of quantity of taken preparations, 14%-control to take reduction of quantity of taken preparations, 14%-control to take -control to take control to take medicines appropriately, 5%-motivation to dose the medicines appropriately The -motivation to dose the medicines appropriately The motivation to dose the medicines appropriately The biggest problem for the responders was making notes on utilization of medicines in a diary (59%). The other expected problems are: informing the pharmacist about the ut the course of pharmacotherapy (24%) and the necessity to follow new rules and being systematic (17%). The conducted survey shows that patients are interested in taking part in the care process and in result they expect notable financial benefits and reduction of the quantity of medicines taken. To implement efficiently the care in pharmacies and to encourage patients to take part in the programme, it is necessary to prepare a message aimed at fulfilment of actual expectations and social needs.
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PHP29 UN POUR TOUT, TOUT POUR UN? AN EMPIRICAL ANALYSIS OF PHARMACEUTICAL COVERAGE DECISIONS IN THREE COUNTRIES
Harris A Monash University, Clayton, VIC, Australia OBJECTIVES: National public insurance coverage of drugs is based on evidence of comparative effectiveness and cost effectiveness. This study compares the importance of these issues across three jurisdictions (Australia, Canada, England and Wales) that have been at the forefront of evidence-based coverage internationally.
METHODS:
A retrospective comparative analysis of data on factors that have been influential in pharmaceutical public insurance coverage decision in England and Wales (NICE), Australia (PBAC) and Canada (CDR) was conducted. The probability of coverage for drugs was compared across jurisdictions by each key factor. Data items on all drugs considered for 2004 to 2008 were extracted from publicly available documents on coverage decisions in each country. RESULTS: Recommendations varied considerably across countries in part because of different processes including the willingness to negotiate on price and the associated attitude to market proliferation of drugs with similar characteristics. The data suggest that the three agencies make recommendations that are consistent with a cost effectiveness framework; although it is clear that these committees have other objectives in addition to efficiency. This is consistent with previous empirical studies that suggest the strength of evidence of the comparative effectiveness of the drug as well the budgetary cost to government is also significant predictors of listing in addition to cost-effectiveness. CONCLUSIONS: NICE, PBAC, and CDR continue to face common issues with respect to the quality and strength of the experimental evidence in support of a clinically meaningful effect. There are significant differences in recommendations across countries in part due to differences in interpretation of evidence differences in objectives and associated processes, particularly with respect to price negotiation.
PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS:
A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK Mansour E 1 , Le Pen C 2 , Nestrigue C 3 , Amalric F 1 1 IMS Health, Puteaux, Ile de France, France, 2 Dauphine University, Paris, France, 3 IMS Health, Puteaux, France OBJECTIVES: 1) Compare the quality of primary care in France to that in the UK through a comparison of the avoidable hospitalization rates in both countries, and 2) f the avoidable hospitalization rates in both countries, and 2) Shed light on the determinants of the quality of primary care through a comparison of practices between the two countries for three Avoidable Hospital Conditions (AHC). METHODS: We counted the total number of hospitalizations for 12 AHCs defined by Weissman et al. Patient hospitalization records were drawn from the PMSI database for France (2006) and the HES database for England (April 2006-May 
